Corporate news

11.05.2026
Marinomed Biotech AG announces progress with Tacrolimus Eyedrops for Entry into the Compounding Market
22.04.2026
Marinomed Announces Strategic Expansion into Compounding Services Featuring Marinosolv® Technology
13.04.2026
Marinomed secures financing through successful capital increase
19.03.2026
Marinomed Biotech Announces Capital increase with subscription rights
Public Relations
Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg, Austria
+43 2262 90300
office@marinomed.com